各案件を、会社自身の開示資料に照らして4つの観点(約束は具体的か、実行の経過を追えるか、経済性を説明しているか、目標に対する結果を報告しているか)で確認しています。評価方法 →
株式による資金調達/2026-05-21
実施中
公表資料を発表・実施・結果の順に記録しています。この表示は選定した案件の調査状況であり、会社全体の評価ではありません。
出典資料1 ・ 出典資料2
Class A preferred shares to DBJ: up to ¥20bn for growth investment
The first ¥10bn series was paid on 31 July 2026 after shareholder approval on 24 June. The second series of up to ¥10bn is drawn on Towa's notice, and the funds are to be spent from August 2026 to March 2028.
時系列と出典(2件・内容は原文)
- 2026-05-21Board resolved issuance Up to ¥20bn of non-voting Class A preferred shares to the Development Bank of Japan in two series of ¥10bn, with a preferred dividend of 4.4% a year; proceeds for growth investment in Towa's own lines and collaborations from August 2026 to March 2028. 出典資料1
- 2026-07-31First series paid Payment of ¥10bn for 10,000 shares completed after approval at the 24 June 2026 AGM; share capital and legal capital surplus reduced by the same amounts. 出典資料1
経営陣が表明したこと
Towa resolved on 21 May 2026 to issue up to ¥20bn of non-voting preferred shares to DBJ at a 4.4% preferred dividend, for growth investment from August 2026 to March 2028.
会社の開示資料による ・ 出典資料1
実際に行ったこと・時期
The first ¥10bn series was paid on 31 July 2026 after AGM approval; the second series is undrawn.
会社の開示資料による ・ 出典資料1
経済性について開示したこと
The notice explains why preferred equity was chosen over common shares or debt, but gives no project-level return.
一部開示(不足あり) ・ 出典資料1
その後の経過
The use of proceeds is not due for review until March 2028.
一部開示(不足あり) ・ 出典資料1
残る論点
Investor question: what returns will the ¥20bn earn, and when will the preferred shares be redeemed? IR preparation: publish a use-of-proceeds table and a redemption plan.
当調査の分析(会社の説明ではありません)
約束は具体的か4/5Amount, series, dividend rate, use and spending period are stated and dated; no return target is attached to the investments.
実行の経過を追えるか4/5Resolution, AGM approval and first-series payment are traceable with amounts; the second series and spending are not yet evidenced.
経済性を説明しているか3/5The notice compares equity, preferred and debt routes and states the 4.4% cost; project returns are not quantified.
目標に対する結果を報告しているか時期未到来The spending period ends in March 2028.
経営計画・資本政策の見直し/2025-05-15
実施中
公表資料を発表・実施・結果の順に記録しています。この表示は選定した案件の調査状況であり、会社全体の評価ではありません。
出典資料1 ・ 出典資料2 ・ 出典資料3
Revision of the 6th Medium-term Business Plan PROACTIVE III targets (May 2025) and progress report (May 2026)
Towa raised the plan's cumulative operating-profit target from ¥68bn to ¥80bn or more in May 2025. A year later, after a ¥14.7bn impairment of Sunsho Pharmaceutical goodwill, it reported operating profit expected slightly below target (¥78.3bn), ROIC below target (5.3% against 6%) and capital expenditure above it (¥79.3bn against ¥60bn). The final year ends in March 2027.
時系列と出典(3件・内容は原文)
- 2025-05-15Targets revised Cumulative operating profit target raised from ¥68bn to ¥80bn or more; final-year sales ¥300bn, ROIC 6% (7% before goodwill), R&D ¥55bn and capex ¥60bn or more unchanged. 出典資料1(英文は日本語版と同日。日本語版 2025-05-15)
- 2026-05-11Impairment recognised ¥14.7bn goodwill impairment on Sunsho Pharmaceutical; FY2025 net profit forecast cut from ¥17.7bn to ¥5.2bn; effect on plan targets to be disclosed with results. 出典資料1(英文は日本語版と同日。日本語版 2026-05-11)
- 2026-05-14Progress reported Against targets: sales ¥304bn (achieved), cumulative operating profit ¥78.3bn (target ¥80bn), ROIC 5.3% / 5.9% (6% / 7%), R&D ¥55.4bn, capex ¥79.3bn (¥60bn); WACC about 5.5%, cost of equity about 8.5%. 出典資料1(英文は日本語版と同日。日本語版 2026-05-14)
経営陣が表明したこと
Towa raised its cumulative operating-profit target for FY2024-FY2026 from ¥68bn to ¥80bn or more in May 2025, keeping the ROIC, R&D and capex targets.
会社の開示資料による ・ 出典資料1(英文は日本語版と同日。日本語版 2025-05-15)
実際に行ったこと・時期
In May 2026 it reported progress against each target: sales achieved, operating profit ¥78.3bn, ROIC 5.3%, capex ¥79.3bn, after a ¥14.7bn Sunsho goodwill impairment.
会社の開示資料による ・ 出典資料1(英文は日本語版と同日。日本語版 2026-05-11) ・ 出典資料2(英文は日本語版と同日。日本語版 2026-05-14)
経済性について開示したこと
It frames returns as ROIC against a WACC of about 5.5% and a cost of equity of about 8.5%, and explains the ROIC shortfall by higher capex, inventory and debt.
会社の開示資料による ・ 出典資料1(英文は日本語版と同日。日本語版 2026-05-14)
その後の経過
The final year ends in March 2027; the company already expects operating profit and ROIC below target.
一部開示(不足あり) ・ 出典資料1(英文は日本語版と同日。日本語版 2026-05-14)
残る論点
Investor question: what return will the excess capex earn? IR preparation: give the projects and their expected returns against the stated WACC.
当調査の分析(会社の説明ではありません)
約束は具体的か5/5Every target is quantified, and the revision shows previous and revised values with reasons.
実行の経過を追えるか4/5The May 2026 deck sets each target against progress and forecast and explains the gaps; the impairment notice deferred the target update by three days, as promised.
経済性を説明しているか4/5ROIC targets with and without goodwill and stated WACC and cost of equity give an economic test; project-level returns are not disclosed.
目標に対する結果を報告しているか時期未到来The final year ends in March 2027; the company has already reported that operating profit and ROIC are expected to fall short.
買収/2026-07-03
実施中
公表資料を発表・実施・結果の順に記録しています。この表示は選定した案件の調査状況であり、会社全体の評価ではありません。
出典資料1 ・ 出典資料2
Acquisition of Tanabe Pharma Factory and 35 product approvals from Tanabe Pharma (agreed July 2026)
Towa agreed to buy all shares of Tanabe Pharma Factory (two plants) and 17 ingredients / 35 product approvals, with the share transfer planned for the end of November 2026 and the approvals from April 2027, subject to antitrust clearance. The price is not disclosed; negative goodwill is expected.
時系列と出典(2件・内容は原文)
- 2026-07-03Acquisition agreed 22,602 shares (100%) and 35 approvals; acquisition costs not disclosed by agreement, negative goodwill expected; target sales ¥15.8bn and operating profit ¥1.1bn in the year to March 2026; capacity goal of 4-5 billion tablets at the plants by FY2036. 出典資料1(英文は日本語版と同日。日本語版 2026-07-03)
- 2026-07-08(公表 2026-07-29)Briefing material in English The presentation (Japanese 8 July) appeared in English on 29 July, with the target's three-year results and plant output. 出典資料1(英文は日本語版の21日後。日本語版 2026-07-08)
経営陣が表明したこと
Towa agreed to buy all shares of Tanabe Pharma Factory and 35 product approvals from Tanabe Pharma to add domestic supply capacity, closing at the end of November 2026 and from April 2027 for the approvals.
会社の開示資料による ・ 出典資料1(英文は日本語版と同日。日本語版 2026-07-03)
実際に行ったこと・時期
The deal is announced and explained in a briefing; closing has not yet happened, and the English briefing materials came three weeks after the Japanese.
一部開示(不足あり) ・ 出典資料1(英文は日本語版と同日。日本語版 2026-07-03) ・ 出典資料2(英文は日本語版の21日後。日本語版 2026-07-08) ・ 出典資料3(英文は日本語版の20日後。日本語版 2026-07-29)
経済性について開示したこと
The price is not disclosed by agreement; the notice gives the target's sales of ¥15.8bn, operating profit of ¥1.1bn and net assets of ¥31.7bn, and expects negative goodwill.
一部開示(不足あり) ・ 出典資料1(英文は日本語版と同日。日本語版 2026-07-03)
その後の経過
The outcome is not due; the company has promised to disclose the negative goodwill and the forecast effect.
一部開示(不足あり) ・ 出典資料1(英文は日本語版と同日。日本語版 2026-07-03)
残る論点
Investor question: what did Towa pay and what will the plants cost to expand? IR preparation: disclose the negative goodwill on closing and the capex plan to 2036.
当調査の分析(会社の説明ではありません)
約束は具体的か3/5Scope, schedule, conditions and capacity goals are stated, but the price is withheld and no financial target is set.
実行の経過を追えるか3/5The notice was same-day in English, but the briefing deck and the Q&A script reached English three weeks after the Japanese.
経済性を説明しているか2/5The target's three-year results are given and negative goodwill is expected, but the price, the capex required and the expected return are not.
目標に対する結果を報告しているか時期未到来The share transfer is planned for the end of November 2026.